Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of QAU145 in patients with cystic fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• QAU145

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED